Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on February 19, 2025, by Jaguar Health, Inc. The report discloses a material definitive agreement entered into on February 13, 2025, involving the Company and its wholly-owned subsidiary, Napo Pharmaceuticals, Inc.
Key Financial Metrics
The filing details a specific debt obligation but does not provide comprehensive financial statements, revenue, profit, or cash flow data for the period.
- Debt Instrument: Secured promissory note with Streeterville Capital, LLC.
- Principal Amount: $6,220,812.50.
- Original Issue Date: January 19, 2021.
- Revised Maturity Date: January 20, 2026.
Material Changes
The primary material change reported is the extension of the maturity date for the existing secured promissory note. The maturity has been extended from its original term to January 20, 2026, pursuant to a Note Amendment executed on February 13, 2025.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the disclosure of the debt obligation itself. The document references the full text of the Note Amendment (Exhibit 4.1) for complete terms.
Investor Verification Checklist
- Verify the full terms of the Note Amendment filed as Exhibit 4.1, including interest rates, covenants, and prepayment conditions.
- Confirm the current status of the $6,220,812.50 principal balance and any accrued interest.
- Review the Company's most recent 10-K or 10-Q for updated liquidity positions and total debt obligations.
- Assess the impact of the extended maturity date on the Company's short-term and long-term liquidity requirements.